Adagene Inc. (NASDAQ:ADAG – Free Report) – Analysts at HC Wainwright issued their FY2029 earnings per share estimates for Adagene in a research note issued to investors on Monday, January 27th. HC Wainwright analyst A. He anticipates that the company will post earnings of ($0.56) per share for the year. HC Wainwright has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Adagene’s current full-year earnings is ($0.65) per share.
Adagene Stock Down 1.1 %
Shares of ADAG stock opened at $1.85 on Tuesday. The business’s fifty day moving average is $2.03 and its 200 day moving average is $2.39. Adagene has a twelve month low of $1.74 and a twelve month high of $3.89.
Institutional Inflows and Outflows
Adagene Company Profile
Adagene Inc, a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors.
Further Reading
- Five stocks we like better than Adagene
- Insider Buying Explained: What Investors Need to Know
- How to Short Sell Stocks Like a Pro: Strategies and Tips
- Investing In Automotive Stocks
- 3 Steel Stocks Soaring After Tariff Announcements
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Top Analysts’ Picks for 2025: 3 of Morgan Stanley’s Favorites
Receive News & Ratings for Adagene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene and related companies with MarketBeat.com's FREE daily email newsletter.